Human Bladder Cancer Peripheral Blood Mononuclear Cells

Description

Human Bladder Cancer Peripheral Blood Mononuclear Cells (PBMCs) are isolated from patients with histologically confirmed urothelial carcinoma, the most common form of bladder cancer representing about 90% of cases. These human-derived PBMCs contain immune cell populations (T cells, B cells, NK cells, monocytes) that demonstrate bladder cancer-specific immune alterations, including elevated exhausted PD-1⁺CD8⁺ T cells and increased Treg population (CD4⁺CD25⁺FoxP3⁺), reflecting the immunosuppressive tumor microenvironment characteristic of this malignancy. The cells exhibit typical mononuclear morphology with intact surface markers and maintain functional cytokine production (IFN-γ, IL-10) in response to tumor antigens. They are particularly valuable for studying the unique immunobiology of bladder cancer, which shows high response rates to immunotherapy but frequent development of resistance. These PBMCs provide a critical platform for investigating immune modulation in bladder cancer, assessing immune response in bladder cancer, evaluating novel therapies involving PBMC bladder cancer, and monitoring inflammation markers in bladder cancer.